The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Bexobrutideg shows durable activity in heavily pretreated CLL
Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, presents updated Phase Ia/b trial data on bexobrutideg in chronic lymphocytic leukemia (CLL), highlighting durable responses and encouraging progression-free survival in heavily pretreated patients previously exposed to BTK and BCL2 inhibitors. He also discusses the ongoing evaluation of this BTK degrader in earlier lines of therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So bexobrutideg is a BTK inhibitor which has been looked at in multiple B-cell histologies. What I will be presenting the data on is the patients with relapsed refractory CLL. There is an update on the longer follow-up on these patients where we are seeing that at 18 months, estimated PFS is around 55% for these patients who have been heavily pretreated with multiple lines of therapy, including covalent BTK inhibitors, non-covalent BTK inhibitors, and BCL2 inhibitors...
So bexobrutideg is a BTK inhibitor which has been looked at in multiple B-cell histologies. What I will be presenting the data on is the patients with relapsed refractory CLL. There is an update on the longer follow-up on these patients where we are seeing that at 18 months, estimated PFS is around 55% for these patients who have been heavily pretreated with multiple lines of therapy, including covalent BTK inhibitors, non-covalent BTK inhibitors, and BCL2 inhibitors. So what we are looking at now is that bexobrutideg was able to salvage these patients and we’re seeing durable responses in a number of patients now. What also will be presented would be the use of the drug in earlier lines of therapy with patients who’ve had no previous line of therapy, as well as a cohort where the only line of therapy was a covalent BTK inhibitor, I’m suggesting that this approach can be used in earlier lines of therapy. And further trials are going to be looking at this question of use of this drug in earlier lines of therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
